Shares of Schrödinger, Inc. (NASDAQ:SDGR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $32.11.
A number of research firms recently weighed in on SDGR. KeyCorp boosted their price target on shares of Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. BMO Capital Markets increased their price target on Schrödinger from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th.
View Our Latest Research Report on SDGR
Hedge Funds Weigh In On Schrödinger
Schrödinger Stock Down 0.8 %
NASDAQ:SDGR opened at $25.67 on Wednesday. The company’s 50-day moving average price is $21.60 and its two-hundred day moving average price is $20.27. Schrödinger has a 12 month low of $16.67 and a 12 month high of $33.63. The firm has a market cap of $1.87 billion, a PE ratio of -10.97 and a beta of 1.61.
Schrödinger (NASDAQ:SDGR – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The company had revenue of $35.30 million for the quarter, compared to the consensus estimate of $41.25 million. During the same period in the prior year, the company earned ($0.86) EPS. The firm’s revenue was down 17.1% compared to the same quarter last year. On average, research analysts expect that Schrödinger will post -2.37 EPS for the current fiscal year.
Schrödinger Company Profile
Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
See Also
- Five stocks we like better than Schrödinger
- Buy P&G Now, Before It Sets A New All-Time High
- 3 Volatility ETFs to Help You Profit from Market Chaos
- Why Invest in High-Yield Dividend Stocks?
- Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
- Market Cap Calculator: How to Calculate Market Cap
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.